γ-干扰素诱生蛋白10与肝病关系研究进展*

doi:10.3969/j.issn.1672-5069.2017.01.034

摘要/Abstract

摘要： 趋化因子γ-干扰素诱生蛋白10 （IP-10)和它的受体CXCR3在肝炎的发生发展过程中起重要作用,并可能对抗病毒治疗疗效的判断提供有益的线索。IP-10可以由多种细胞分泌,如T淋巴细胞、NK细胞、内皮细胞和肝实质细胞等。在病毒性肝炎发生的过程中,IP-10通过直接或间接作用于病毒特异性T细胞和NK细胞等效应细胞,趋化它们到肝组织局部发生免疫应答,发挥抗病毒作用。IP-10的分泌同时也会促进病毒性肝炎发展成为肝纤维化、肝硬化。在抗病毒药物治疗的患者中,血清基线IP-10水平与治疗后病毒DNA载量以及抗原滴度呈负相关关系,对于抗病毒药物治疗后免疫应答反应起了一定的预测作用。IP-10在肝病的发生发展过程中的具体作用机制还需要更深入的研究。

关键词: 慢性乙型肝炎, γ-干扰素诱生蛋白10, 细胞因子

Abstract: Interferon （IFN）-γ-induced protein 10 （IP-10/CXCL10） and its receptor CXCR3,appear to contribute to the pathogenesis of viral hepatitis. CXCL10 could be secreted by various cells,including T cells,NK cells,endothelial cells,hepatocytes,etc. It plays an essential role in recruiting specific T cells,NK cells and other effector cells to local inflammatory sites to control the infection by through direct or indirect interactions. IP-10 expression is also correlated with developing liver fibrosis and cirrhosis from viral hepatitis. Furthermore,high level of IP-10 in baseline has shown a clinical utility as a predictor of effective outcome of anti-viral therapy. Since the mechanism of how IP-10 modulates anti-viral responses remains unknown, further studies are still needed to investigate the interaction between IP-10 and leukocytes in the pathogenesis of hepatitis,and to evaluate whether IP-10 could be a novel therapeutic target of viral diseases.

Key words: Hepatitis B, Interferon -γ-induced protein 10, cytokines

赵凯综述, 商庆华, 宋文刚审校. γ-干扰素诱生蛋白10与肝病关系研究进展^*[J]. 实用肝脏病杂志, 2017, 20(1): 120-123.

Zhao Kai, Shang Qinghua, Song Wengang. Progress in interferon -γ-induced protein 10 in pathogenesis of liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 120-123.

参考文献

[1] 丁红晖,郝友华,杨新星,等. HBV感染者血清趋化因子IP-10和RANTES的表达及其临床意义探讨.实用肝脏病杂志,2009,12（3）：176-178.
[2] Brownell J,Polyak SJ. Molecular pathways:hepatitis C virus,CXCL10,and the inflammatory road to liver cancer. Clin Cancer Res,2013,19（6）:1347-1352.
[3] Oo YH,Shetty S,Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis,2010,28（1）:31-44.
[4] Chen LJ,Lyu J,Wen XY,et al. CXC chemokine IP-10: a key actor in liver disease Hepatol Int,2013,7（3）:798-804.
[5] Chang CC,Wu CL,Su WW,et al. Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Sci Rep,2015,5:10096.
[6] Balmasova IP,Sepiashvili RI,Malova ES,et al. Molecular biology of hepatitis B virus and immunopath ogenesis of chronic viral hepatitis B. Zh Mikrobiol Epidemiol Immunobiol,2016,32（2）:119-126.
[7] Van Raemdonck K,Van den Steen PE,Liekens S,et al. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev,2015,26（3）:311-327.
[8] Chai Q,She R,Huang Y,et al. Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells,production of chemokines and cytokines,and enhancement of blood-brain barrier permeability. J Virol,2015, 89（1）:870-876.
[9] Martinet J,Dufeu-Duchesne T,Costa JB,et al. Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology,2012,143（6）:1586-1596.
[10] Liu M,Guo S,Hibbert JM,et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev,2011,22（3）:121-130.
[11] Kakimi K,Lane TE,Wieland S,et al. Blocking chemokine responsive to γ 2/interferon（IFN）-γ inducible protein and monokine induced by IFN-γ activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus specific cytotoxic T lymphocytes. J Exp Med,2001,194（12）:1755-1766.
[12] Ito H,Ando T,Ando K,et al. Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2,3-dioxygenase activity. Immunology,2014,142（4）:614-623.
[13] Xu ZH,Liu Y,Liu LM,et,al. Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population.PLoS One,2013,8（9）:e72799.
[14] Gong LL,Zhao BB,Fan WF,et al.Correlations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians.Int J Clin Exp Pathol,2015,8（7）:8367-8375.
[15] Wang J,Zhao JH,Wang PP,et al. Expression of CXC chemokine IP-10 in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int,2008,7（1）:45-50.
[16] Mihm S,Schweyer S,Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN γ and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol,2003,70（4）:562-570.
[17] Antonelli A,Ferrari SM,Corrado A,et al. CXCR3,CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev,2014,25（1）:57-65.
[18] Sayed-Ahmed L,Kotb N,El-Serogy H,et al. TNF-αand CXCL-10 correlation with insulin resistance in patients with chronic hepatitis C virus infection.Egypt J Immunol,2010,17（1）:101-111.
[19] Carlin AF,Aristizabal P,Song Q,et al.Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection. Hepatology,2015,62（4）:1047-1058.
[20] Abe T,Fukuhara T,Wen X,et al. CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating,through an interaction with Toll-like receptor 2 and hyaluronan. J Virol,2012,86（11）:6159-6170.
[21] Wiegand SB,Jaroszewicz J,Potthoff A,et al. Dominance of hepatitis C virus （HCV） is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect,2015,21（7）:710.
[22] Goh CC,Roggerson KM,Lee HC,et al. Hepatitis C virus-induced myeloid-derivedsuppressor cellssuppress NK Cell IFN-γ production by altering cellular metabolism via Arginase-1. J Immunol,2016,196（5）:2283-2292.
[23] Hintermann E,Bayer M,Pfeilschifter JM,et al. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J Autoimmun,2010,35（4）:424-435.
[24] Wang J,Wang PP,Xiang GJ,et al. Relationship between the expression of IP-10 and IP-10 mRNA in peripheral blood and HBV DNA level in patients with cirrhosis.Hepatobiliary Pancreat Dis Int,2010,9（3）:280-286.
[25] Saudy N,Shahin D,Zakaria S,et al. Serum interferon-gamma inducible protein-10:a possible player in progression of hepatitis B virus related chronic liver diseases.Int J Adv Res（Indore）,2015,3（7）:602-611.
[26] Sevgi DY,Bayraktar B,Gündüz A,et al. Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. Wien Klin Wochenschr,2016,128（1-2）:28-33.
[27] Nishikawa H,Enomoto H,Iwata Y,et al. B-cell activating factor belonging to the tumor necrosis factor family and interferon-g-inducible protein-10 in autoimmune hepatitis.Medicine （Baltimore）,2016,95（12）:e3194.
[28] Willemse SB,Jansen L,de Niet A,et al. Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir. Antiviral Res,2016,131:148-155.
[29] Papatheodoridis G,Triantos C,Hadziyannis E,et al. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate. Antivir Hepat,2015,22（12）:1079-1087.
[30] Jaroszewicz J,Ho H,Markova A,et al. Hepatitis B surface antigen（HBsAg） decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther, 2011,16（6）:915-924.
[31] Hou FQ,Wu XJ,Wang Y,et al. Rapid downregulation of programmed death-1 and interferon-c-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.J Viral Hepat,2013,20 （1）:18-26.
[32] Sonneveld MJ,Arends P,Boonstra A,et al. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol,2013,58（5）:898-903.
[33] Chokshi S,Cooksley H,Riva H,et al. Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption.Viral Immunol,2014,27（5）:235-244.
[34] Wang Y,Zhao C,Zhang L,et al. Predictive value of interferon-gamma inducible protein 10kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. Antiviral Res,2014,103:51-59.
[35] Chen J,Wang Y,Li J,et al. Pegylated interferon-2b up-regulates specific CD8 + T cells in patients with chronic hepatitis B. World J Gastroenterol,2010,16（48）:6145-6150.
[36] Papatheodoridis G,Goulis J,Manolakopoulos SC,et al. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.J Hepatol, 2014,60（1）:62-68.

γ-干扰素诱生蛋白10与肝病关系研究进展^*

Progress in interferon -γ-induced protein 10 in pathogenesis of liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[6]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[7]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[8]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[13]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[14]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.